S. 526 119th Congress
Pharmacy Benefit Manager Transparency Act of 2025
Latest action, Feb 11, 2025: Read twice and referred to the Committee on Commerce, Science, and Transportation.
How the Senate voted
The Senate hasn't taken a roll call on this bill in the Congresses covered.
14 cosponsors
Sponsored by Chuck Grassley (Republican). Cosponsors by party, House members included:
- Democrats
- Republicans
- Independents
Cosponsors
6 D · 8 R
- Democrat
- Republican
- Independent
Referred to: Senate: Commerce, Science, and Transportation Committee
Who lobbied on it
Clients whose quarterly lobbying reports named it, each quarter.
The clients with the most reports naming it. A report's amount covers all of that client's lobbying in the quarter, not just this bill.
7 reports
AMAC ACTION, INC.
SCHOENING STRATEGIES, LLC
7 reports
7 reports
7 reports
7 reports
6 reports
SOUTHEAST GEORGIA HOSPITAL SYSTEM
CAROL G HOLLADAY & ASSOCIATES
6 reports
4 reports
4 reports
The top 25 of 27 clients, by reports
| Client | Lobbying firm | Reports | Reports totaling | From | To | Senate |
|---|---|---|---|---|---|---|
| ALZHEIMER'S ASSOCIATION | 7 | $7.7M | Q1 2025 | Q3 2026 | yes | |
| AMAC ACTION, INC. | SCHOENING STRATEGIES, LLC | 7 | $0 | Q1 2025 | Q3 2026 | yes |
| AMERICA'S HEALTH INSURANCE PLANS INC (AHIP) | 7 | $28.6M | Q1 2025 | Q3 2026 | yes | |
| AMERICAN COLLEGE OF RHEUMATOLOGY | 7 | $610K | Q1 2025 | Q3 2026 | yes | |
| AMERICAN MEDICAL ASSOCIATION | 7 | $40.8M | Q1 2025 | Q3 2026 | yes | |
| ASSOCIATION FOR CLINICAL ONCOLOGY | 7 | $1.9M | Q1 2025 | Q3 2026 | yes | |
| NATIONAL COMMUNITY PHARMACISTS ASSOCIATION | 7 | $2.2M | Q1 2025 | Q3 2026 | yes | |
| PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION | 7 | $23.2M | Q1 2025 | Q3 2026 | yes | |
| ELEVANCE HEALTH, INC. | 6 | $11.5M | Q1 2025 | Q2 2026 | yes | |
| NATIONAL ASSOCIATION OF CHAIN DRUG STORES | 6 | $2.5M | Q1 2025 | Q3 2026 | yes | |
| SOUTHEAST GEORGIA HOSPITAL SYSTEM | CAROL G HOLLADAY & ASSOCIATES | 6 | $120K | Q1 2025 | Q2 2026 | yes |
| BIOTECHNOLOGY INNOVATION ORGANIZATION | 5 | $8.9M | Q1 2025 | Q3 2026 | yes | |
| THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) | 5 | $11.9M | Q1 2025 | Q1 2026 | yes | |
| INDEPENDENT PHARMACY COOPERATIVE | 4 | $170K | Q4 2025 | Q3 2026 | yes | |
| PRIME THERAPEUTICS | 4 | $720K | Q1 2025 | Q3 2025 | yes | |
| AMERICAN PHARMACIES, INC. | ROBERTI GLOBAL (F/K/A ROBERTI WHITE, LLC) | 3 | $180K | Q4 2025 | Q1 2026 | yes |
| MIGHTY THERAPEUTICS (FMRLY STEALTH BIOTHERAPEUTICS INC.) | 3 | $270K | Q1 2025 | Q3 2025 | yes | |
| ALBERTSONS COMPANIES, INC. | 2 | $1.1M | Q1 2025 | Q2 2025 | yes | |
| AMERICAN BENEFITS COUNCIL | 2 | $550K | Q2 2026 | Q3 2026 | yes | |
| BRISTOL-MYERS SQUIBB COMPANY | 2 | $8.0M | Q2 2025 | Q3 2025 | yes | |
| CROHN'S & COLITIS FOUNDATION | 2 | $80K | Q2 2026 | Q3 2026 | yes | |
| PFIZER INC. | 2 | $8.0M | Q1 2025 | Q2 2025 | yes | |
| SOLENO THERAPEUTICS, INC. | THE KPM GROUP DC LLC | 2 | $100K | Q4 2025 | Q3 2025 | yes |
| THE CIGNA GROUP AND SUBSIDIARIES (FKA CIGNA CORPORATION AND SUBSIDIARIES) | BANNER PUBLIC AFFAIRS, LLC | 2 | $40K | Q1 2025 | Q2 2025 | yes |
| AARP | 1 | $6.6M | Q1 2025 | Q1 2025 | yes |